Christopher B Fox

Summary

Affiliation: Infectious Disease Research Institute
Country: USA

Publications

  1. doi Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA, USA
    Int J Nanomedicine 9:1367-77. 2014
  2. pmc Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
    H W Millie Fung
    IDRI, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, USA
    J Nanobiotechnology 11:43. 2013
  3. ncbi TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
    Christopher B Fox
    Infectious Disease Research Institute, 1616 Eastlake Avenue, Suite 400, Seattle, WA 98102, USA Electronic address
    Vaccine 31:5848-55. 2013
  4. doi Charged aerosol detection to characterize components of dispersed-phase formulations
    Christopher B Fox
    Infectious Disease Research Institute, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, United States Electronic address
    Adv Colloid Interface Sci 199:59-65. 2013
  5. doi An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
    Christopher B Fox
    IDRI, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, USA
    Expert Rev Vaccines 12:747-58. 2013
  6. doi Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 31:1633-40. 2013
  7. pmc Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 19:1633-40. 2012
  8. doi Characterization of TLR4 agonist effects on alhydrogel® sedimentation: a novel application of laser scattering optical profiling
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    J Pharm Sci 101:4357-64. 2012
  9. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
  10. pmc Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011

Collaborators

Detail Information

Publications27

  1. doi Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA, USA
    Int J Nanomedicine 9:1367-77. 2014
    ..Employing a suite of complementary analytical techniques is important to fully characterize interactions between vaccine components. ..
  2. pmc Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
    H W Millie Fung
    IDRI, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, USA
    J Nanobiotechnology 11:43. 2013
    ..This nanosuspension is a clinical vaccine adjuvant known as GLA-AF. We examined the effects of DPPC supplier, buffer composition, and manufacturing process on GLA-AF physicochemical and biological activity characteristics...
  3. ncbi TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses
    Christopher B Fox
    Infectious Disease Research Institute, 1616 Eastlake Avenue, Suite 400, Seattle, WA 98102, USA Electronic address
    Vaccine 31:5848-55. 2013
    ..g. TLR ligands) on the resulting immune responses to adjuvanted vaccines and may play a critical role for combating diseases where T cell immunity is advantageous. ..
  4. doi Charged aerosol detection to characterize components of dispersed-phase formulations
    Christopher B Fox
    Infectious Disease Research Institute, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, United States Electronic address
    Adv Colloid Interface Sci 199:59-65. 2013
    ..In particular, we discuss the advantages and disadvantages of CAD compared to other HPLC detection methods, as well as the various sample preparation methods suitable for colloidal formulations prior to HPLC-CAD analysis. ..
  5. doi An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants
    Christopher B Fox
    IDRI, 1616 Eastlake Ave E, Ste 400, Seattle, WA 98102, USA
    Expert Rev Vaccines 12:747-58. 2013
    ..Overall, emulsion adjuvants have demonstrated potent adjuvant activity across a number of disease indications along with acceptable safety profiles. ..
  6. doi Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 31:1633-40. 2013
    ....
  7. pmc Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 19:1633-40. 2012
    ..Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose...
  8. doi Characterization of TLR4 agonist effects on alhydrogel® sedimentation: a novel application of laser scattering optical profiling
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    J Pharm Sci 101:4357-64. 2012
    ....
  9. pmc Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  10. pmc Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  11. doi Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington 98104, USA
    Pharm Dev Technol 16:511-9. 2011
    ..Substitution of naturally derived egg phosphatidylcholine with synthetic 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) produced an emulsion with similar physicochemical properties and stability...
  12. doi Squalene emulsions for parenteral vaccine and drug delivery
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Molecules 14:3286-312. 2009
    ..The safety of squalene-based products is also addressed. Finally, analytical techniques for characterization of squalene emulsions are examined...
  13. doi Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
    Ryan C Anderson
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Colloids Surf B Biointerfaces 75:123-32. 2010
    ....
  14. ncbi Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Colloids Surf B Biointerfaces 65:98-105. 2008
    ..It is shown that oil-in-water emulsions using animal-derived components can be substituted with synthetic or plant-derived materials while still exhibiting satisfactory physicochemical and biological properties...
  15. pmc Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  16. doi Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Influenza Other Respir Viruses 7:815-26. 2013
    ..However, few reports have been published that systematically evaluate the in vitro stability and in vivo adjuvant effects of different emulsion components...
  17. pmc Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
    Mark T Orr
    Infectious Disease Research Institute, Seattle 98104, USA
    J Control Release 172:190-200. 2013
    ..These results demonstrate that there are multiple solutions for an effective formulation of a novel TB vaccine candidate that enhances both TH1 generation and protective efficacy. ..
  18. doi Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization
    Mark T Orr
    Infectious Disease Research Institute, Seattle, WA 98102, USA Electronic address
    J Control Release 177:20-6. 2014
    ....
  19. doi Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
    ..Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model...
  20. ncbi A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7
    Christopher B Fox
    Infectious Disease Research Institute IDRI, Seattle, WA, USA
    J Nanobiotechnology 12:17. 2014
    ..Ligands of each of these TLRs generally have disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle...
  21. doi Modulating potency: physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity
    Quinton M Dowling
    Infectious Disease Research Institute, Seattle, Washington, 98102
    J Pharm Sci 103:879-89. 2014
    ..We discuss these data in light of the current understanding of TLR4 activation and the conformation-potency relationship in development of adjuvanted vaccines...
  22. doi Use of defined TLR ligands as adjuvants within human vaccines
    Malcolm S Duthie
    Infectious Disease Research Institute, Seattle, WA, USA
    Immunol Rev 239:178-96. 2011
    ....
  23. pmc In vitro evaluation of TLR4 agonist activity: formulation effects
    Ayesha Misquith
    Infectious Disease Research Institute IDRI, 1124 Columbia Street, Ste 400, Seattle, WA 98104, USA
    Colloids Surf B Biointerfaces 113:312-9. 2014
    ..Furthermore, we discuss the formulation considerations which should be taken into account when interpreting data from in vitro adjuvant activity assays. ..
  24. pmc A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93
    Mark T Orr
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 9:e83884. 2014
    ..Finally we demonstrate that this adjuvant synergy between GLA and CpG is independent of TRIF signaling, whereas TRIF is necessary for the adjuvant activity of GLA-SE in the absence of CpG. ..
  25. doi Key roles of adjuvants in modern vaccines
    Steven G Reed
    Infectious Disease Research Institute, Seattle, Washington, USA
    Nat Med 19:1597-608. 2013
    ..Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases. ..
  26. doi Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, USA
    Subcell Biochem 53:303-21. 2010
    ..Moreover, the formulation of TLR4 agonists has been shown to significantly affect the type and magnitude of elicited immune response. TLR4 agonists comprise a promising class of adjuvants for safe and effective vaccines...
  27. pmc Adjuvants for Leishmania vaccines: from models to clinical application
    Vanitha S Raman
    Pre clinical Biology, Infectious Disease Research Institute, Seattle, WA, USA
    Front Immunol 3:144. 2012
    ....